Osteopontin-c isoform levels are associated with SR and hnRNP differential expression in ovarian cancer cell lines
Open Access
- 22 September 2017
- journal article
- Published by IOS Press in Tumor Biology
- Vol. 39 (9)
- https://doi.org/10.1177/1010428317725442
Abstract
Osteopontin-c splicing isoform activates ovarian cancer progression features. Imbalanced expression of splicing factors from serine/arginine -rich and heterogeneous ribonucleoproteins families has been correlated with the generation of oncogenic splicing isoforms. Our goal was to investigate whether there is any association between the transcriptional patterns of these splicing factors in ovarian cells and osteopontin-c expression levels. We also aimed to investigate the occurrence of these splicing factors binding sites inside osteopontin exon 4 and adjacent introns. To test associations between osteopontin-c and splicing factors expression patterns, we used an in vitro model in which OVCAR-3 cells overexpressing osteopontin-c (OVCAR-3/OPNc++) presented higher transcriptional levels of osteopontin-c than two other ovarian carcinoma cells (TOV-112D, SKOV-3) and ovarian non-tumoral cell lines (IOSE 364 and IOSE 385). The transcriptional levels of osteopontin-c, serine/arginine-rich, and hnRNP factors were evaluated using real-time polymerase chain reaction. Human Splice Finder software was used to search for putative splicing factor binding sites in osteopontin genomic regions. OVCAR-3/OPNc++ cells presented higher transcriptional levels of hnRNP than serine/arginine-rich when compared to TOV-112D, SKOV-3, and IOSE cells. TOV-112D and SKOV-3 cells also overexpressed hnRNP in relation to serine/arginine-rich transcripts. Putative binding sites for these splicing factors have been predicted on osteopontin exon 4 and their upstream and downstream intronic regions. Our data showed that higher osteopontin-c expression levels are associated with a predominance of hnRNP in relation to serine/arginine-rich transcripts and that osteopontin exon 4 and adjacent intronic sequences contain predicted binding sites for some of these tested splicing factors. In conclusion, differential expression of these splicing factors in ovarian cancer cells could be one of the putative mechanisms leading to aberrant splicing of the osteopontin primary transcript. Future work, aiming to control ovarian cancer progression by downregulating osteopontin-c levels, could include strategies that also regulate heterogeneous ribonucleoproteins and serine/arginine-rich expression levels in order to modulate osteopontin splicing.Keywords
This publication has 29 references indexed in Scilit:
- Differential connectivity of splicing activators and repressors to the human spliceosomeGenome Biology, 2015
- Alternative splicing in cancer: implications for biology and therapyOncogene, 2014
- Hallmarks of alternative splicing in cancerOncogene, 2013
- Regulation of alternative splicing by local histone modifications: potential roles for RNA-guided mechanismsNucleic Acids Research, 2013
- Alterations in Expression Pattern of Splicing Factors in Epithelial Ovarian Cancer and its Clinical ImpactInternational Journal of Gynecologic Cancer, 2013
- The function of the RNA-binding protein hnRNP in cancer metastasisJournal of Cancer Research and Therapeutics, 2013
- Alternative Splicing Regulation and Cell Lineage DifferentiationCurrent Stem Cell Research & Therapy, 2012
- Disturbed Expression of Splicing Factors in Renal Cancer Affects Alternative Splicing of Apoptosis Regulators, Oncogenes, and Tumor SuppressorsPLOS ONE, 2010
- hnRNP Proteins and Splicing ControlAdvances in Experimental Medicine and Biology, 2007
- Alternative Splicing of the Multidrug Resistance Protein 1/ATP Binding Cassette Transporter Subfamily Gene in Ovarian Cancer Creates Functional Splice Variants and Is Associated with Increased Expression of the Splicing Factors PTB and SRp20Clinical Cancer Research, 2004